Garcia, A. M.; Brea, J.; González-García, A.; Pérez, C.; Cadavid, M. I.; Loza, M. I.; Martinez, A.; Gil C.
[2017]. Targeting PDE10A GAF domain with small molecules: a way for allosteric modulation with anti-inflammatory effects. Molecules 2017, 22, 1472. doi:10.3390/molecules22091472.
Sebastián-Pérez, V.; Roca, C.; Awale, M.; Reymond, J. L.; Martínez, A.; Gil, C.; Campillo, N. E.
[2017]. The Medicinal and Biological Chemistry (MBC) library: an efficient source on new hits. J. Chem. Inf. Model. 2017, 57, 2143-2151.
Morales-Garcia, J.; Salado, I. G.; Sanz-San Cristobal, M.; Gil, C.; Pérez-Castillo, A.; Martínez, A.; Pérez, D. I.
[2017]. Biological and pharmacological characterization of Benzothiazole based CK-1δ inhibitors in models of Parkinson’s disease. ACS Omega 2017, 2, 5215-5220.
Salado, I. G.; Zaldivar-Diez, J.; Sebastian, V.; Li, L.; Geiger, L.; González, S.; Campillo, N. E.; Morales, A. V.; Perez, D. I.; Martinez, A.
[2017]. Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. Eur. J. Med. Chem. 2017, 138, 328-342.
Palomo, V.; Perez, D. I.; Roca, C.; Anderson, C.; Rodriguez-Muela, N.; Perez, C.; Morales-Garcia, J. A.; Reyes, J. A.; Campillo, N. E.; Perez-Castillo, A. M.; Rubin, L. L.; Timchenko, L. T.; Gil, C.; Martinez, A.
[2017]. Subtly modulating Glycogen Synthase Kinase 3 beta: allosteric inhibitors development and their potential for the treatment of chronic diseases. J. Med. Chem. 2017, 60, 4983-5001.
Garcia, A. M.; Salado, I. G.; Perez, D. I.; Brea, J.; Morales-García, J. M.; González-García, A.; Cadavid, M. I.; Loza, M. I.; Luque, F. J.; Perez-Castillo, A.; Martinez, A.; Gil, C.
[2017]. New pharmacological tools based on imidazole scaffold proved the utility of Phosphodiesterase 10 (PDE10) inhibitors for Parkinson’s disease treatment. Fut. Med. Chem. 2017, 9, 707-810.
Guerra, A.; Gonzalez-Naranjo, P.; Campillo, N. E. Varela, J.; Lavaggi, M. L.; Merlino, A. Cerecetto, H.; González, M.; Gomez-Barrio, A.; Escario, J.A.; Fonseca-Berzal, C.; Yaluf, G.; Paniagua, J.; Páez, J.
[2017]. Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties. Eur. J. Med. Chem. 2017 136, 223-234
Contreras, A.; Del Rio, D.; Martinez, A.; Gil, C.; Morales, L.; Ruiz-Gayo, M.; Del Olmo, N.
[2017]. Inhibition of hippocampal long-term potentiation by high-fat diets: is it related to an effect of palmitic acid involving glycogen synthase kinase-3?. Neuroreport 2017, 28, 354-359.
Monjas, L.; Arce, M. P.; León, R.; Egea, J.; Pérez, C.; Villarroya, M.; López, M. G.; Gil, C.; Conde, S.; Rodríguez-Franco, M. I.
[2017]. Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. Eur. J. Med. Chem. 2017, 130, 60-72.
Mansilla, A.; Chavez-Sanjuán, A.; Campillo, N. E.; Semelidou, O.; Martínez-González, L.; Infantes, L.; Gil, C.; Conde, S.; Skoulakis, E. M. C.; Ferrús, A.; Martinez, A.; Sánchez-Barrena, M. J.
[2017]. Phenothiazines regulate synaptic function by interfering the NCS-1/Ric8a complex: a novel approach for Fragile X Syndrome. PNAS 2017, 114, E999-E1008.
Medina-Rodríguez, E. M.; Bribián, A.; Boyd, A.; Palomo, V.; Pastor, J.; Lagares, A.; Gil, C.; Martínez, A.; Williams, A.; de Castro, F.
[2017]. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci. Rep. 2017, 7, 43545.
Martinez, A.; Palomo, V.; Perez, D.I.; Gil, C.
[2017]. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Exp. Opin. Inv. Drugs 2017, 26, 403-414
Ponzoni, I.; Sebastian, V.; Requena, C., Roca, C.; Martínez, M. J. ; F. Cravero, F.; Díaz, M. F.; Páez, J. A.; Gomez-Arrayas, R.; Adrio, J.; Campillo, N. E.
[2017]. Hybridizing feature selection and featurelLearning approaches in QSAR modeling for drug discovery. Sci. Rep. 2017, 7, 2403.
Marchena, M.; Villarejo-Zori, B.; Zaldivar-Diez, J.; Palomo, V.; Gil, C.; Hernandez-Sanchez, C.; Martinez, A.; de la Rosa, E.J.
[2017]. Small molecules targeting Glycogen Synthase Kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. J. Enz. Inh. Med. Chem. 2017, 32, 522-526.
Martín-Álvarez, R.; Paúl-Fernández, N.; Palomo, V.; Gil, C.; Martinez, A.; Mengod, G.
[2017]. A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. J. Chem. Neuroanat. 2017, 80, 27-36
Pérez-Domper, P.; Palomo, V.; Gradari, S.; Gil, C.; de Ceballos, M. L.; Martínez, A.; Trejo, J. L.
[2017]. The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology 2017, 116, 174-187.
Barbado, M. V.; Medrano, M.; Caballero-Velazquez, T.; Alvarez-Laderas, I.; Sanchez-Abarca, L. I.; Garcia-Guerrero, E.; Martin-Sanchez, J.; Rosado, I. V.; Piruat, J. I.; Gonzalez-Naranjo, P.; Campillo, N. E.; Paez, J. A.; Perez-Simon, J. A.
[2017]. Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo. Int. J. Cancer 2017, 140, 674-685.
Pardo, M.; Cheng, Y.; Velmeshev, D.; Magistri, M.; Eldar-Finkelman, H.; Martinez, A.; Faghihi, M.; Jope, R.S.; Beurel, E.
[2017]. Intranasal siRNA administration can regulate learning and ameliorate deficits in Fragile X syndrome mice. J Clinical Investigation Insight, 2017, 2(6):e91782.
Chierrito, T.; Pedersoli-Mantoani, S.; Roca, C.; Requena, C.; Sebastian-Perez, V.; Castillo, W.; Moreira, N.; Perez, C.; Sakamoto, E.; Takashashi, C.; Jimenez-Barbero, J.; Cañada, F.J.; Campillo, N.E.; Martinez, A.; Carvalho, I.
[2017]. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer’s disease. Eur. J. Med. Chem. 2017, 39, 773-791
